参考文献/References:
[1] Lindsey ML. Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling [J]. Nat Rev Cardiol,2018,15(8):471-479.
[2] Seropian IM,Toldo S,van Tassell BW,et al. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction[J]. J Am Coll Cardiol,2014,63(16):1593-1603.
[3] Su JH,Luo MY,Liang N,et al. Interleukin-6:a novel target for cardio-cerebrovascular diseases[J]. Front Pharmacol,2021,12:745061.
[4] Hilfiker-Kleiner D,Shukla P, Klein G,et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation,left ventricular rupture,and adverse outcome in subacute myocardial infarction[J]. Circulation,2010,122(2):145-155.
[5] Chen GY,Nu?ez G. Sterile inflammation:sensing and reacting to damage[J]. Nat Rev Immunol,2010,10(12):826-837.
[6] Hammerman H,Kloner RA,Hale S,et al. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent,scar formation,and ventricular function[J]. Circulation,1983,68(2):446-452.
[7] Kleveland O,Kunszt G,Bratlie M,et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction:a double-blind,randomized,placebo-controlled phase 2 trial[J]. Eur Heart J,2016,37(30):2406-2413.
[8] Broch K,Anstensrud AK,Woxholt S,et al. Randomized trial of interleukin-6 receptor inhibition in patients with?acute ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol,2021,77(15):1845-1855.
[9] Deftereos S,Giannopoulos G,Angelidis C,et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction:a pilot study [J]. Circulation,2015,132(15):1395-1403.
[10] Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
[11] Becirovic-Agic M,Chalise U,Daseke MJ 2nd,et al. Infarct in the heart:what’s MMP-9 got to do with it?[J]. Biomolecules,2021,11(4):491.
[12] van den Borne SW,Cleutjens JP,Hanemaaijer R,et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction[J]. Cardiovasc Pathol,2009,18(1):37-43.
[13] Ibarra-Lara L ,Sánchez-Aguilar M,Soria-Castro E,et al. Clofibrate treatment decreases inflammation and reverses myocardial infarction-induced remodelation in a rodent experimental model[J]. Molecules,2019,24(2):270.
[14] Nielsen SH,Mouton AJ,Deleon-Pennell KY,et al. Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes[J]. Matrix Biol,2019,75-76:43-57.
[15] Gao XM,Tsai A,Al-Sharea A,et al. Inhibition of the renin-angiotensin system post myocardial infarction prevents inflammation-associated acute cardiac rupture[J]. Cardiovasc Drugs Ther,2017,31(2):145-156.
[16] Gao XM,Dilley RJ,Samuel CS,et al. Lower risk of postinfarct rupture in mouse heart overexpressing beta 2-adrenergic receptors:importance of collagen content[J]. J Cardiovasc Pharmacol,2002,40(4):632-640.
[17] Ichihara S,Senbonmatsu T,Price E Jr,et al. Targeted deletion of angiotensinⅡtype 2 receptor caused cardiac rupture after acute myocardial infarction[J]. Circulation,2002,106(17):2244-2249.
[18] Chute M,Aujla PK,Li Y,et al. ADAM15 is required for optimal collagen cross-linking and scar formation following myocardial infarction[J]. Matrix Biol,2022,105:127-143.
[19] Wu X,Liu Z,Yu XY,et al. Autophagy and cardiac diseases:therapeutic potential of natural products[J]. Med Res Rev,2021,41(1):314-341.
[20] Aisa Z,Liao GC,Shen XL,et al. Effect of autophagy on myocardial infarction and its mechanism[J]. Eur Rev Med Pharmacol Sci,2017,21(16):3705-3713.
[21] Wu D,Z hang K,H u P. The role of autophagy in acute myocardial infarction[J]. Front Pharmacol,2019,10:551.
[22] 王佳南,林建安,杜苗苗. 丹参酮ⅡA对急性心肌梗死大鼠心脏功能和心肌线粒体自噬的影响[J]. 中国免疫学杂志,2019,35(4):418-423.
[23] 郭红,徐臣年,张勇,等. 姜黄素激活哺乳动物西罗莫司靶蛋白信号抑制自噬减轻小鼠心肌梗死损伤的作用[J]. 中国临床药理学杂志,2021,37(22):3097-3101.
[24] 杨永康,李静,饶廷彩,等. 金丝桃苷通过调节自噬水平减轻心肌梗死小鼠心脏及胸主动脉的损伤[J]. 中国临床药理学与治疗学,2021,26(6):601-608.
[25] Hua J,Liu Z,Liu Z,et al. Metformin increases cardiac rupture after myocardial infarction via the AMPK-MTOR/PGC-1α signaling pathway in rats with acute myocardial infarction[J]. Med Sci Monit,2018,24:6989-7000.
[26] Wang X,Guo Z,Ding Z,et al. Inflammation,autophagy,and apoptosis after myocardial infarction[J]. J Am Heart Assoc,2018,7(9):e008024.
[27] Baldi A,Abbate A,Bussani R,et al. Apoptosis and post-infarction left ventricular remodeling[J]. J Mol Cell Cardiol,2002,34(2):165-174.
[28] Abbate A,Bussani R,Biondi-Zoccai GG,et al. Infarct-related artery occlusion,tissue markers of ischaemia,and increased apoptosis in the peri-infarct viable myocardium[J]. Eur Heart J,2005,26(19):2039-2045.
[29] Duran JM,Makarewich CA,Trappanese D,et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction[J]. Circ Res,2014,114(11):1700-1712.
[30] Luo T,Kim JK,Chen B,et al. Attenuation of ER stress prevents post-infarction-induced cardiac rupture and remodeling by modulating both cardiac apoptosis and fibrosis[J]. Chem Biol Interact,2015,225:90-98.
[31] 公威,李奥博,马友才,等. 内质网应激介导的凋亡参与急性心肌梗死后心脏破裂的作用及机制[J]. 中国医药,2020,15(6):830-834.
[32] Zhou H,Toan S. Pathological roles of mitochondrial oxidative stress and mitochondrial dynamics in cardiac microvascular ischemia/reperfusion injury[J]. Biomolecules,2020,10(1):85.
[33] Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection[J]. Free Radic Biol Med,2018,117:76-89.
[34] Cui X,Liang H,Hao C,et al. Liraglutide preconditioning attenuates myocardial ischemia/reperfusion injury via homer1 activation[J]. Aging(Albany NY),2021,13(5):6625-6633.
[35] Chen WR,Chen YD,Tian F,et al. Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction[J]. Circ Cardiovasc Imaging,2016,9(12):e005146.
[36] Nauck MA,Meier JJ,Cavender MA,et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors[J]. Circulation,2017,136(9):849-870.
[37] Piot C,Croisille P,Staat P,et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction[J]. N Engl J Med,2008,359(5):473-481.
[38] Cung TT,Morel O,Cayla G,et al. Cyclosporine before PCI in patients with acute myocardial infarction[J]. N Engl J Med,2015,373(11):1021-1031.
[39] Kalkhoran SB,Kriston-Vizi J,Hernandez-Resendiz S,et al. Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission[J]. Cardiovasc Res,2022,118(1):282-294.
[40] Ma S,Lu Q,Hu H,et al. Post-infarct left ventricular thrombosis is mechanistically related to ventricular wall rupture[J]. Med Hypotheses,2020,144:109938.
[41] Hausenloy DJ,Chilian W,Crea F,et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury:a target for cardioprotection[J]. Cardiovasc Res,2019,115(7):1143-1155.
[42] Du XJ,Shan L,Gao XM,et al. Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction[J]. Thromb Haemost,2011,105(2):356-364.
[43] Liu T,Howarth AG,Chen Y,et al. Intramyocardial hemorrhage and the "wave front" of reperfusion injury compromising myocardial salvage[J]. J Am Coll Cardiol,2022,79(1):35-48.
[44] Becker RC,Charlesworth A,Wilcox RG,et al. Cardiac rupture associated with thrombolytic therapy:impact of time to treatment in the Late Assessment of Thrombolytic Efficacy(LATE) study[J]. J Am Coll Cardiol,1995,25(5):1063-1068.
[45] van Leeuwen MAH,van der Hoeven NW,Janssens GN,et al. Evaluation of microvascular injury in revascularized patients with ST-segment-elevation myocardial infarction treated with ticagrelor versus prasugrel[J]. Circulation,2019,139(5):636-646.
[46] El FarissI M,Keulards DCJ,Zelis JM,et al. Hypothermia for reduction of myocardial reperfusion injury in acute myocardial infarction:closing the translational gap[J]. Circ Cardiovasc Interv,2021,14(8):e010326.
[47] Wang W,Wang B,Sun S,et al. Inhibition of adenosine kinase attenuates myocardial ischaemia/reperfusion injury[J]. J Cell Mol Med,2021,25(6):2931-2943.
[48] Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective[J]. Nat Rev Cardiol,2020,17(12):773-789.
[49] Kolpakov MA,Guo X,Rafiq K,et al. Loss of protease-activated receptor 4 prevents inflammation resolution and predisposes the heart to cardiac rupture after myocardial infarction[J]. Circulation,2020,142(8):758-775.
[50] Zuurbier CJ,Bertrand L,Beauloye CR,et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction[J]. J Cell Mol Med,2020,24(11):5937-5954.
相似文献/References:
[1]林远龙,刘现亮.无复流现象:从基础到临床[J].心血管病学进展,2016,(1):53.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
LIN Yuanlong,LIU Xianliang.From Bench to Bed:No-reflow Phenomenon[J].Advances in Cardiovascular Diseases,2016,(7):53.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
[2]赵劲东,综述,董平栓,等.合并多支血管病变的急性ST段抬高型心肌梗死介入术治疗策略的研究进展[J].心血管病学进展,2016,(3):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
ZHAO Jindong,DONG Pingshuan.Research Progress of Interventional Therapy in Patients with ST-elevation
Myocardial Infarction and Multivessel Disease[J].Advances in Cardiovascular Diseases,2016,(7):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
[3]余正春,综述,马小静,等.急性心肌梗死并发心源性休克的治疗进展[J].心血管病学进展,2016,(4):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
YU Zhengchun,MA Xiaojing.Treatment of Cardiogenic Shock Complicating Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(7):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
[4]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(7):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[5]元洋洋 李波.Selvester QRS评分系统研究进展[J].心血管病学进展,2019,(7):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
YUAN YangyangLI Bo.Research Progress of Selvester QRS Scoring System[J].Advances in Cardiovascular Diseases,2019,(7):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
[6]翁子骞 于波.血栓抽吸在急性ST段抬高型心肌梗死中的研究进展[J].心血管病学进展,2019,(7):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
WENG ZiqianYU Bo.Thrombus aspiration in acute ST-segment elevation myocardial infarction[J].Advances in Cardiovascular Diseases,2019,(7):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
[7]杨颜瑜,苏星,谭敏,等.炎症指标与急性心肌梗死研究进展[J].心血管病学进展,2019,(6):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
YANG Yanyu,SU Xing,TAN Min,et al.Relationship Between Inflammation Index and Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(7):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
[8]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(7):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[9]潘甜 马康华.急性心肌梗死经皮冠脉介入术后冠状动脉无复流的预防和治疗进展[J].心血管病学进展,2019,(5):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
PAN Tian,MA Kanghua.Prevention and Treatment of Coronary Artery No-Reflow after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(7):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
[10]朱建中 吴倩芸 刘峰.急性ST段抬高型心肌梗死“导管室误激活”的临床进展[J].心血管病学进展,2019,(5):739.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.019]
ZHU JianzhongWU QianyunLIU Feng.The Development of False-positive Activation of Cardiac Catheterization Laboratory with Acute ST Segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(7):739.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.019]
[11]林莉 韦铁民.急性心肌梗死后心脏破裂[J].心血管病学进展,2019,(7):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
LIN LiWEI Tiemin.Post-infarction Cardiac Rupture[J].Advances in Cardiovascular Diseases,2019,(7):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]